UK markets closed

Inventiva S.A. (IVA)

NasdaqGM - NasdaqGM Real-time price. Currency in USD
Add to watchlist
14.28-0.22 (-1.52%)
As of 9:30AM EDT. Market open.
Full screen
Trade prices are not sourced from all markets
Previous close14.50
Open13.98
Bid14.12 x 1200
Ask14.50 x 3000
Day's range14.28 - 14.28
52-week range10.52 - 19.06
Volume1,138
Avg. volume40,267
Market cap581.806M
Beta (5Y monthly)0.88
PE ratio (TTM)N/A
EPS (TTM)-1.41
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
  • Globe Newswire

    Inventiva announces the presentation of five scientific abstracts at the AASLD The Liver Meeting™ 2021

    Four poster presentations add to the evidence of the beneficial effects of lanifibranor therapy on key components of NASH, following further sub-analyses of Inventiva’s NATIVE Phase IIb clinical trial resultsThe fifth poster presentation demonstrates that lanifibranor improves NASH, fibrosis and diastolic dysfunction in a hamster model of diet-induced NASH and diastolic dysfunction Daix (France), Long Island City (New York, United States), October 18, 2021 – Inventiva (Euronext Paris and Nasdaq:

  • Globe Newswire

    Inventiva announces participation at several investor conferences in October 2021

    Daix (France), Long Island City (New York, United States), September 28, 2021 – Inventiva (Euronext Paris and Nasdaq: IVA), a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis (NASH), mucopolysaccharidoses (MPS) and other diseases with significant unmet medical need, today announced that the Company’s leadership will participate in three upcoming investor conferences in October 2021. The event d

  • Globe Newswire

    Inventiva completes sale of $30 million through its ATM program to existing and new specialized institutional investors

    Sale performed at a price of $14.40 per new ADS1 , without a discount to the volume weighted average price of the Company's ADS over the last trading day Daix (France), Long Island City (New York, United States), September 23, 2021 – Inventiva (Euronext Paris and Nasdaq: IVA) (the "Company"), a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis (NASH), mucopolysaccharidoses (MPS) and other diseas